WO2011064758A3 - Fusion proteins of immunoglobulin fc and interferon- alpha - Google Patents

Fusion proteins of immunoglobulin fc and interferon- alpha Download PDF

Info

Publication number
WO2011064758A3
WO2011064758A3 PCT/IB2010/055474 IB2010055474W WO2011064758A3 WO 2011064758 A3 WO2011064758 A3 WO 2011064758A3 IB 2010055474 W IB2010055474 W IB 2010055474W WO 2011064758 A3 WO2011064758 A3 WO 2011064758A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
alpha
immunoglobulin
fusion proteins
fusion protein
Prior art date
Application number
PCT/IB2010/055474
Other languages
French (fr)
Other versions
WO2011064758A2 (en
Inventor
Giuseppe Ciaramella
Maria Victoria Flores
Nigel John Horscroft
Madan Katragadda
Yanli Wu
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of WO2011064758A2 publication Critical patent/WO2011064758A2/en
Publication of WO2011064758A3 publication Critical patent/WO2011064758A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides an interferon-alpha immunoglobulin Fc fusion protein and use of the fusion protein in the treatment of a condition alleviated by the administration of interferon- alpha, such as a liver disorder, for example hepatitis and in particular hepatitis C.
PCT/IB2010/055474 2009-11-30 2010-11-29 Fusion protein WO2011064758A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26500109P 2009-11-30 2009-11-30
US61/265,001 2009-11-30

Publications (2)

Publication Number Publication Date
WO2011064758A2 WO2011064758A2 (en) 2011-06-03
WO2011064758A3 true WO2011064758A3 (en) 2011-08-04

Family

ID=43640103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/055474 WO2011064758A2 (en) 2009-11-30 2010-11-29 Fusion protein

Country Status (1)

Country Link
WO (1) WO2011064758A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456809A (en) * 2013-12-03 2017-02-22 韦尔特生物分子医药有限责任公司 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
BR112015018104A2 (en) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc modified gdf15 polypeptides, their use, compositions comprising them and sterile container comprising said compositions
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
BR112016002213A2 (en) 2013-07-31 2017-08-29 Amgen Inc CONSTRUCTS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF-15)
LT6164B (en) * 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Fused proteins of interferon alpha 5 with another cytokine and process for production thereof
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
EA035581B1 (en) 2014-07-30 2020-07-10 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Compositions and methods of use for treating metabolic disorders
TN2017000113A1 (en) 2014-10-31 2018-07-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
PE20190126A1 (en) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc BINDING PROTEINS AND METHODS OF USING THEM
CN107254482A (en) * 2017-07-18 2017-10-17 哈尔滨紫霞生物科技有限公司 A kind of method for improving Recombinant Swine interferon alpha fusion protein antiviral activity
CN107177613A (en) * 2017-07-18 2017-09-19 哈尔滨紫霞生物科技有限公司 A kind of method for improving restructuring Porcine interferon-gamma fusion protein antiviral activity
CN107129994A (en) * 2017-07-18 2017-09-05 哈尔滨紫霞生物科技有限公司 A kind of method for improving canine recombinant interferon beta fusion protein antiviral activity
CN107326037A (en) * 2017-07-18 2017-11-07 哈尔滨紫霞生物科技有限公司 A kind of method for improving Recombinant Swine interferon beta fusion protein antiviral activity
MX2020010659A (en) 2018-04-09 2020-10-28 Amgen Inc Growth differentiation factor 15 fusion proteins.
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058572A1 (en) * 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2002072605A2 (en) * 2001-03-07 2002-09-19 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2004074486A2 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
WO2006127757A2 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-igg fusion
WO2008140477A2 (en) * 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058572A1 (en) * 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2002072605A2 (en) * 2001-03-07 2002-09-19 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2004074486A2 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
WO2006127757A2 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-igg fusion
WO2008140477A2 (en) * 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARAI R ET AL: "Design of the linkers which effectively separate domains of a bifunctional fusion protein", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 8, 1 August 2001 (2001-08-01), pages 529 - 532, XP002334380, ISSN: 0269-2139, DOI: DOI:10.1093/PROTEIN/14.8.529 *
JONES T D ET AL: "THE DEVELOPMENT OF A MODIFIED HUMAN IFN-ALPHA2B LINKED TO THE FC PORTION OF HUMAN IGG1 AS A NOVEL POTENTIAL THERAPEUTIC FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 24, no. 9, 1 September 2004 (2004-09-01), pages 560 - 572, XP009055485, ISSN: 1079-9907 *
KOYAMA T ET AL: "Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication", HEPATOLOGY RESEARCH, AMSTERDAM, NL, vol. 34, no. 1, 1 January 2006 (2006-01-01), pages 41 - 49, XP025177312, ISSN: 1386-6346, [retrieved on 20060101], DOI: DOI:10.1016/J.HEPRES.2005.10.005 *
LO K-M ET AL: "High level expression and secretion of Fc-X fusion proteins in mammalian cells", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 6, 1 June 1998 (1998-06-01), pages 495 - 500, XP002125745, ISSN: 0269-2139, DOI: DOI:10.1093/PROTEIN/11.6.495 *
WANG L ET AL: "Enhanced circulation half-life for human IFNa2b and IgG Fc fusion protein", SHENG WU GONG CHENG XUE BAO = CHINESE JOURNAL OF BIOTECHNOLOGY, KEXUE CHUBANSHE, CN, vol. 24, no. 1, 25 January 2008 (2008-01-25), pages 53 - 62, XP008134213, ISSN: 1000-3061 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456809A (en) * 2013-12-03 2017-02-22 韦尔特生物分子医药有限责任公司 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof
CN106456809B (en) * 2013-12-03 2020-02-07 韦尔特生物分子医药有限责任公司 Antibody targeting IgM bound to B cell receptor complex membrane and use thereof

Also Published As

Publication number Publication date
WO2011064758A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2011064758A3 (en) Fusion proteins of immunoglobulin fc and interferon- alpha
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
PH12016500081A1 (en) Immunoglobulin variants and uses thereof
WO2014026054A3 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2014028777A3 (en) Methods of treating a tauopathy
WO2012020006A3 (en) Anti-fap antibodies and methods of use
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
WO2010020766A3 (en) Interleukin fusion polypeptides
NZ705370A (en) Fcγriib-specific fc region variant
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
WO2010106180A3 (en) Optimized fc variants
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2008157378A8 (en) Rage fusion proteins
WO2012046061A3 (en) Clostridium difficile antigens
WO2012139134A3 (en) Methods of modulating oncogenic fusion proteins
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
WO2013003649A3 (en) Wap domain fusion polypeptides and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805639

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10805639

Country of ref document: EP

Kind code of ref document: A2